Application of Radionuclide Labeled Fibroblast Activating Protein Inhibitors in diagnosis of rheumatoid arthritis

Application of Radionuclide Labeled Fibroblast Activating Protein Inhibitors in rheumatoid arthritis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072607

Enrollment

Unknown

Registered

2023-06-19

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non neoplastic Lesions

Interventions

Research Group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All rheumatoid arthritis patients aged = 18 years voluntarily participated in the study and signed the FAPI-PET/CT imaging informed consent form in writing.

Exclusion criteria

Exclusion criteria: Critically ill patients, those with respiratory depression, airway obstruction or tissue hypoxia; Drug and/or alcohol abusers, allergic individuals; Those who cannot tolerate and cooperate with the examination; Those who, in the judgment of the researcher, are not suitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Maximum uptake value of positive tissue;	—

Countries

China

Contacts

Public ContactLiMeng

Affiliated Hospital of Guilin Medical University

617046440@qq.com+86 185 8994 3640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026